Quantcast
Last updated on April 18, 2014 at 9:20 EDT

Latest Tamoxifen Stories

2014-04-03 12:56:51

Women who took clomiphene citrate (brand name Clomid) or gonadotropins as a part of fertility treatment did not experience an increased risk for breast cancer over 30 years of follow-up, compared with women who were not treated with these medications, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. "We wanted to evaluate the long-term relationship of fertility medications and breast cancer risk...

2014-04-03 08:30:01

Joins Renowned Academic Scientists Charles Sawyers, Jose Baselga and Ronald Evans SAN DIEGO, April 3, 2014 /PRNewswire/ -- Seragon Pharmaceuticals Inc., a clinical-stage biotechnology company focused on the development of drugs for hormone-driven cancers, today announced the expansion of the company's Clinical and Scientific Advisory Board (CSAB) and the appointment of Debasish Roychowdhury, M.D., who will serve as Seragon's Acting Chief Medical Officer....

Gregory Tsongalis PhD
2014-03-26 03:00:14

Norris Cotton Cancer Center, Dartmouth College Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer. The paper entitled "Personalized Therapy for Breast Cancer" was accepted on March 17, 2014, for publication in Clinical Genetics. The paper discusses targeted therapies, new biomarkers, and the quality of commercially available testing methods....

2014-03-25 08:31:12

MIAMI and NEW YORK, March 25, 2014 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,658,663, entitled "Method Of Treating Thermoregulatory Dysfunction With Paroxetine." This method of use patent covers the company's Brisdelle(®) (paroxetine) capsules, 7.5 mg, for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, commonly referred to as hot flashes....

2014-03-24 08:28:34

SAN DIEGO, March 24, 2014 /PRNewswire/ -- Seragon Pharmaceuticals Inc., a clinical-stage biotechnology company focused on the development of drugs for hormone-driven cancers, today announced the appointment of N. Anthony Coles (Tony), M.D. to the company's Board of Directors. Dr. Coles brings nearly 30 years of experience in the healthcare, biotechnology and pharmaceutical industries. Most recently, Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of...

2014-02-11 10:53:30

Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more HIV/AIDS patients than tuberculosis, appear in mBio®, the online open-access journal of the American Society for Microbiology (ASM.) "This work sets the stage for additional animal studies to see if tamoxifen can be used as a drug in people and will allow us to design...

2014-01-29 08:30:15

SAN DIEGO, Jan. 29, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced that it has performed its first 3D Liver tissue delivery. The achievement marks the delivery of Organovo's 3D Liver tissue to a laboratory outside of the company to a key opinion leader (KOL) for experimentation, and marks the achievement of a milestone along the pathway to commercial...

2014-01-17 23:03:42

Certain medications can reduce a woman's risk for developing breast cancer. Women at high risk for breast cancer should talk with their doctors about this strategy. Boston, MA (PRWEB) January 17, 2014 Many new and potent medicines to prevent breast cancer have become available in the past 20 years. Surprisingly, many women—even those at high risk for the disease—are not taking advantage of these medicines, according to an article in the January 2014 issue of the Harvard...

2014-01-13 08:30:09

FLORHAM PARK, N.J., Jan. 13, 2014 /PRNewswire/ -- Shionogi Inc. today announced that it has entered into an exclusive, multi-year agreement with Noven Pharmaceuticals to co-promote Brisdelle(TM) (paroxetine) capsules, 7.5 mg, the first and only non-hormonal prescription drug approved for the treatment of moderate to severe hot flashes associated with menopause. Under the terms of the agreement, Shionogi will promote Brisdelle, along with Osphena(TM) (ospemifene), its non-estrogen oral...

2014-01-13 08:29:50

Co-Promotion to Extend Physician Awareness of the First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Menopausal Hot Flashes MIAMI and NEW YORK, Jan. 13, 2014 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that it has entered into an agreement with Shionogi Inc. to co-promote Brisdelle(TM) (paroxetine) capsules, 7.5 mg. The agreement will help extend physician awareness of the first and only FDA-approved, non-hormonal treatment for moderate to severe...